Voltaren

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Voltaren

What is Voltaren

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a type of non-steroidal anti-inflammatory drug (NSAID) used to manage pain and inflammation. It works by inhibiting the enzymes that produce prostaglandins, which are substances involved in pain and inflammation. Diclofenac is usually prescribed as a first line treatment for acute and chronic pain and inflammation caused by a variety of conditions. It is often combined with misoprostol to prevent stomach ulcers. Diclofenac was approved by the FDA in 1988 under the brand name Voltaren, and is produced by Novartis.

Voltaren

is the brand name

image of different drug pills on a surface

Voltaren Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Voltaren Affects Patients

Diclofenac helps to reduce pain and fever caused by inflammation. Unfortunately, taking this drug can also increase the risk of stomach ulcers because it reduces the amount of protective mucus in the stomach.

How Voltaren works in the body

Diclofenac works by preventing the production of prostaglandins, molecules that play a role in pain and inflammation. This has a number of effects on both the periphery and centrally in the brain. In the periphery, diclofenac reduces pain sensitivity, stops white blood cells from flowing to sites of inflammation, and reduces the production of inflammatory molecules. In the brain, diclofenac reduces heat-generation, reducing the activity of neurons that trigger fever. All of these effects work together to reduce pain and inflammation.

When to interrupt dosage

The recommended dosage of Voltaren is contingent upon the determined condition, including Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The dose fluctuates as per the technique of delivery (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) noted in the table beneath.

Condition

Dosage

Administration

Wounds, Nonpenetrating

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Fever

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Surgery, Dental

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Muscle Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Osteoarthritis of the Knee

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Sprains and Strains

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Musculoskeletal System

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Solution / drops - Ophthalmic, Solution / drops, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated - Oral, Tablet, film coated, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Kit - Topical, Oral; Topical, Kit - Oral; Topical, Tablet, coated, Drug delivery system, Drug delivery system - Topical, Tablet, coated - Oral, Sublingual

Warnings

Voltaren has twenty-nine contraindications, so it should not be taken in combination with any of the circumstances outlined in the subsequent table.

Voltaren Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Voltaren.

Common Voltaren Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Voltaren Toxicity & Overdose Risk

Overdosing on Voltaren can lead to symptoms such as fatigue, nausea, vomiting, upper abdominal pain, and bleeding from the digestive tract. In rare cases, patients may experience high blood pressure, kidney damage or failure, difficulty breathing, or coma. Treatments for Voltaren overdose include inducing vomiting and activated charcoal, as long as the overdose occurred within the last 4 hours.

image of a doctor in a lab doing drug, clinical research

Voltaren Novel Uses: Which Conditions Have a Clinical Trial Featuring Voltaren?

491 active clinical trials are being conducted to examine the potential of Voltaren in relieving Inflammation, argon laser trabeculoplasty and ameliorating Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

57 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3

Osteoarthritis of the Knee

77 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

116 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Not Applicable, Phase 3

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

2 Actively Recruiting

Phase 4, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

5 Actively Recruiting

Not Applicable

Pain

2 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Voltaren Reviews: What are patients saying about Voltaren?

5

Patient Review

1/24/2022

Voltaren for Joint Damage causing Pain and Loss of Function

This was my first time using this medication, and I found it to be very effective in alleviating pain.

5

Patient Review

1/24/2022

Voltaren for Joint Damage causing Pain and Loss of Function

I was really pleased with how quickly this medication worked to relieve my pain.

4.7

Patient Review

3/6/2022

Voltaren for Osteoarthritis of the Knee

Volteran is effective at treating my pain and stiffness in my knee.

4.7

Patient Review

3/6/2022

Voltaren for Osteoarthritis of the Knee

Volteran has quickly alleviated the pain and stiffness in my knee after a few applications.

4.3

Patient Review

7/28/2021

Voltaren for Joint Damage causing Pain and Loss of Function

I've been using this for a few years now, as recommended by an orthopedic surgeon. It does a great job of quickly reducing my shoulder and knee pain from arthritis so that I can sleep. However, the effects don't last that long. Still, it's better than nothing until something else comes along.

4.3

Patient Review

5/5/2022

Voltaren for Osteoarthritis of the Knee

I found Voltaren to be very helpful in managing my arthritis pain, though it was not a cure-all. I would definitely use it again if needed. I'm curious as to why there are never any women shown in the advertisements for this product.

4.3

Patient Review

6/21/2022

Voltaren for Joint Damage causing Pain and Loss of Function

Voltaren gel has been a godsend for my rheumatoid arthritis. It helps with the pain and I find that taking it in conjunction with naproxen works best for me.

4.3

Patient Review

5/5/2022

Voltaren for Osteoarthritis of the Knee

I found Voltaren very helpful in treating my arthritic knee. My pain was significantly reduced, though not entirely gone. I would definitely use it again if needed. I am curious as to why there are never any women shown using the product in advertisements, however.

4.3

Patient Review

6/21/2022

Voltaren for Joint Damage causing Pain and Loss of Function

Voltaren gel has been a great help for my rheumatoid arthritis. The pain relief is noticeable and lasts a while. I usually take naproxen first, and then follow up with Voltaren.

4.3

Patient Review

7/28/2021

Voltaren for Joint Damage causing Pain and Loss of Function

Voltaren has been a real lifesaver for me. It quickly reduces the pain I experience from arthritis and lets me get a good night's sleep. The downside is that it doesn't last very long, but I haven't found anything else that works as well yet.

4

Patient Review

5/25/2022

Voltaren for Osteoarthritis of the Knee

At first, I wasn't really sure if this was working. But after a few days of using it, I noticed a significant difference in the pain levels of my knee. It's been amazing and has allowed me to walk again without pain.

4

Patient Review

5/25/2022

Voltaren for Osteoarthritis of the Knee

It took a little while to notice the effects of this treatment, but after using it for a few days, I really saw a difference in my knee pain. It's been great!

3.3

Patient Review

11/4/2021

Voltaren for Osteoarthritis of the Knee

Unfortunately, this medication caused me a lot of pain in my stomach area and also led to some bleeding when using the restroom.

3.3

Patient Review

11/4/2021

Voltaren for Osteoarthritis of the Knee

Caused me severe stomach pain and made it difficult to use the restroom without bleeding.

2.3

Patient Review

7/2/2022

Voltaren for Osteoarthritis of the Knee

I tried this for my arthritis pain and found that it didn't provide any relief whatsoever. Additionally, I would have appreciated a cooling effect, but there was none of that to be found either.

2.3

Patient Review

7/2/2022

Voltaren for Osteoarthritis of the Knee

I have some arthritis pain in my left knee. I used this product on it as directed, but felt no cooling effect whatsoever. Most importantly, though, is that it did nothing to relieve the soreness and tightness in my knee.

1

Patient Review

10/24/2021

Voltaren for Osteoarthritis of the Knee

The possible side effects of this medication are really scary and not worth the risk, in my opinion. Why would I take something that could potentially kill me?

1

Patient Review

1/17/2022

Voltaren for Osteoarthritis of the Knee

I was overcharged for the product and 100 grams is too much. The customer service didn't take my issue seriously.

1

Patient Review

10/24/2021

Voltaren for Osteoarthritis of the Knee

After reading the information that came with this medication, I decided not to risk any of the potential side effects. You may not see results for a week, and in that time you could potentially do serious damage to your heart, kidneys, or stomach--or even die. Advil is a much safer option.

1

Patient Review

1/17/2022

Voltaren for Osteoarthritis of the Knee

I was overcharged for the product and 100grams is too much. The customer service didn't take my complaint seriously enough.

Patient Q&A Section about voltaren

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Voltaren a painkiller or an anti-inflammatory?

"Voltaren products, which can be bought without a prescription, contain diclofenac. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting the production of prostaglandins. Prostaglandins are substances in the body that cause pain and inflammation."

Answered by AI

Is Voltaren the same as ibuprofen?

"Voltaren is available by prescription only.

Are ibuprofen and Voltaren the same drug?

Ibuprofen and Voltaren are both nonsteroidal anti-inflammatory drugs (NSAIDs) that are used to treat pain, fever, and inflammation. Ibuprofen is available in generic form and over-the-counter (OTC), while Voltaren is only available by prescription. Brand names for ibuprofen include Advil and Motrin."

Answered by AI

Is Voltaren a strong painkiller?

"Voltaren is a stronger medication than NSAIDs like ibuprofen, but not as strong as opioid medications like codeine and morphine. Voltaren can cause side effects such as headaches, diarrhea, and dizziness."

Answered by AI

What is Voltaren good for?

"Voltaren Emulgel can be used to relieve pain and inflammation due to sprains, strains, sports injuries, and soft tissue rheumatism."

Answered by AI

Clinical Trials for Voltaren

Image of Alberta Children's Hospital in Calgary, Canada.

Therapeutic Cuddling for Pain in Critically Ill Children

< 65
All Sexes
Calgary, Canada

2.1 CONTEXT Pain and agitation are common comorbidities of pediatric critical illness due to both underlying disease processes and ICU related therapies. These are associated with both short and long term negative sequelae including increased mortality, length of stay, rates of ICU delirium, worse sleep, increased anxiety, depression, and chronic pain. The current standard of care to manage PICU associated pain and agitation is the use of analgosedation (e.g. opioids and benzodiazepines) these too are associated with increased time on the ventilator, length of stay, ICU delirium, and long term mental health and negative neuro-cognitive outcomes. Despite recommendations for increased use of non-pharmacologic therapies in the prevention and management of PICU associated pain, agitation, delirium, and analgosedation exposure, there are currently know therapies with clear evidence of efficacy. Therapeutic cuddling (e.g. kangaroo care, clothed cuddling, comfort holding, etc.) has been shown to decrease pain and anxiety in critically ill neonates, and healthy children and adults. Positive affective touch and hugging has known physiologic benefits and has been associated with decreased pain, improved immunity, and decreased mortality. Despite the potential for this intervention to aid in the prevention and management of PICU associated pain, agitation, delirium and analgosedation exposure, little data exists on efficacy of therapeutic cuddling in critically ill children. 2.2 OBJECTIVES 2.2.1 Primary Determine the feasibility of screening, consent, randomization, and retention of participants in a pragmatic RCT of therapeutic cuddling versus standard of care in the Alberta Children's Hospital Pediatric Intensive Care Unit. 2.2.2 Secondary 1. Determine treatment fidelity of participants randomized to the intervention arm. 2. Determine the prevalence of the therapeutic cuddling intervention in those randomized to the standard of care arm. 3. Determine the feasibility of measurement of key outcomes and co-variates (i.e., pain, agitation, sedation, delirium, analgosedation exposure, parental presence). 4. Describe the experience of patients, caregivers, and healthcare professionals in delivering/receiving the therapeutic cuddling intervention. 2.3 STUDY DESIGN Pilot feasibility randomized controlled trial of a structured co-designed therapeutic cuddling intervention as compared to the standard of care in a single tertiary care PICU. 2.4 DURATION 6 months to 1 year 2.5 LOCATION, DEPARTMENTS, AND FACILITY WHERE RESEARCH WILL BE UNDERTAKEN The pediatric intensive care unit at the Alberta Children's Hospital 2.6 SAMPLE SIZE A total sample size of 112 participants (56 per arm)

Recruiting
Has No Placebo

Alberta Children's Hospital

Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of Hopital general de Montreal in Montreal, Canada.

Nurse-led Telehealth for Rheumatoid Arthritis

18+
All Sexes
Montreal, Canada

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable. This new approach involves nurses helping patients check their own health from home using an online platform. 104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages. This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Waitlist Available
Has No Placebo

Hopital general de Montreal (+3 Sites)

Laetitia Michou, MD PhD

Have you considered Voltaren clinical trials?

We made a collection of clinical trials featuring Voltaren, we think they might fit your search criteria.
Go to Trials
Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Have you considered Voltaren clinical trials?

We made a collection of clinical trials featuring Voltaren, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Epidural Steroid Injections for Back Pain

Any Age
All Sexes
Chicago, IL

Back pain is the leading cause of disability and military medical boards across the globe. Epidural steroid injections (ESI) are the most commonly performed pain procedure in the world. There is strong evidence that the placebo effect for all pain treatments, including ESI, is greater than the intrinsic effect. The placebo effect is highly dependent on a patient's 'expectations', and therefore how the procedure is framed. This study aims to compare ESI when the procedure is framed very positively- as is often done in clinical practice vs. more neutrally (which is less commonly done in clinical practice but consistent with evidence). The placebo effect is also stronger for procedures than medications. The evidence on the benefits of ESI is highly dependent on whether it is compiled by interventional doctors who perform the procedure or non-interventional researchers. In order to determine how 'framing' a treatment affects pain outcomes, the investigative team will conduct a 3-arm randomized trial comparing positive framing of ESI, neutral framing of ESI, and medications, in patients with lumbosacral radiculopathy.

Recruiting
New This Month

Northwestern University (+1 Sites)

Steven P Cohen, MD

Image of University of Miami in Miami, United States.

Steroid Injections for Radiating Back Pain

18+
All Sexes
Miami, FL

This study aims to evaluate the efficacy of interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, to evaluate the efficacy of interlaminar steroid injections at improving quality of life and function in lumbar radiculopathy at varying doses, and to evaluate difference in efficacy between triamcinolone and dexamethasone interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, with the overarching hypotheses that there is no difference in reported pain reduction, quality of life, or function among patients receiving low, moderate, or high doses, and no difference in reported pain reduction between triamcinolone and dexamethasone.

Phase 4
Waitlist Available

University of Miami

Seyed A mostoufi, MD

Have you considered Voltaren clinical trials?

We made a collection of clinical trials featuring Voltaren, we think they might fit your search criteria.
Go to Trials